Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
IPHA(NASDAQ:IPHA) MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces its participation in the 25th edition of the European Midcap Event
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
IPHAMARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Innate Pharma Highlights Long-Term Clinical Benefit Of Lacutamab In Sézary Syndrome And Mycosis Fungoides At ASCO 2025
IPHAInnate Pharma Highlights Continued Oncology Advancements at ASCO 2025 With Lacutamab, IPH4502, And AstraZeneca's NeoCOAST-2 Data
IPHAInnate Pharma Announces Selection Of IPH6501 ANKET Abstract For EHA 2025, Emphasizing Novel NK Cell Engagement Strategy
IPHAInnate Pharma Reports Q1 Revenue Of €1.2M, €72.5M Cash Position Excluding €15M Sanofi Investment; Highlights Progress Across ANKET® And ADC Programs With Runway To Mid-2026
IPHAInnate Pharma Presents New Preclinical Data For IPH4502 AACR Annual Meeting 2025; IPH4502 Shows Strong Preclinical Activity Across Multiple Tumor Types
IPHAFrench Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
IPHASanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Lowers Price Target to $11
IPHAInnate Pharma Confirms €15M Capital Increase Backed By Sanofi To Advance ANKET® Autoimmune Pipeline
IPHAInnate Pharma Regains SAR'579 Rights For AML As Sanofi Proposes €15M Strategic Equity Investment
IPHAInnate Pharma Proposes Transition To CEO And Board Of Directors Governance Model At May 22 Annual General Meeting
IPHAHC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
IPHAInnate Pharma FY EPS $(0.65) Down From $(0.10) YoY, Sales $22.54M Down From $66.35M YoY
IPHAInnate's IPH4502 Demonstrates Preclinical Efficacy In Hard-To-Treat Tumors, Gains Spotlight At AACR Annual Meeting
IPHAInnate Pharma Granted U.S. FDA Breakthrough Therapy Designation To Lacutamab For Relapsed Or Refractory Sézary Syndrome
IPHAInnate Pharma Unveils Transformative Strategy Focused On ANKET Platform, ADC Development, And Strategic Partnerships
IPHAInnate Pharma Publishes Preclinical Data Demonstrating The Potential Of IPH6501 In Science Immunology
IPHAHC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
IPHA